Abstracts tagged "dermatomyositis"

Abstract Number: 1178 • ACR Convergence 2021
Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
Mavra Masood, Fnu Nutan, Julia Nunley and Beth Rubinstein, Virginia Commonwealth University, Richmond, VA
Background/Purpose: There is a dearth of resources for medical students on identifying skin findings of autoimmune disorders in skin of color. Considering how several rheumatologic…
Abstract Number: 0706 • ACR Convergence 2021
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Madison Grinnell¹, Emily Keyes², DeAnna Diaz², Thomas Vazquez³, Rui Feng⁴ and Victoria Werth², ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ³FIU Wertheim College of Medicine, Virginia Beach, VA, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Treatment of dermatomyositis (DM) typically follows a stepwise sequence starting with either methotrexate (MTX) or mycophenolate mofetil (MMF) after an inadequate response to antimalarial…
Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Jason Melehani¹, Shufeng Li², Joshua Mooney³ and Lorinda Chung², ¹Stanford University, San Jose, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
Abstract Number: 1067 • ACR Convergence 2020
Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease
Takahisa Gono¹, Yuka Okazaki¹ and Masataka Kuwana², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with interstitial lung disease (ILD), which often represents rapidly progressive course and fatal outcomes. Circulating levels…
Abstract Number: 1988 • ACR Convergence 2020
Skin Disease More Recalcitrant to Intervention Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis
Andi Wang¹, Gabrielle Morgan², Chiang-Ching Huang³, Amy Paller⁴ and Lauren Pachman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Joseph J. Zilber School of Public Health, Milwaukee, ⁴Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, ⁵Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL
Background/Purpose: Persistent skin manifestations, in particular calcinosis, contribute to significant morbidity in patients with JDM. The goal of this study was to compare the course…
Abstract Number: 1068 • ACR Convergence 2020
Efficacy of Early Initiation of Plasma Exchange Therapy for a Patient with Anti-MDA5 Autoantibody-Positive Dermatomyositis Developing Refractory Rapidly Progressive Interstitial Lung Disease
Noriko Sasaki¹, Akira Ishii¹, Keigo Shimura¹, Azusa Kojima¹, Mai Sugiyama², Yuto Izumi¹, Kazuki Hirano¹, Sho Sasaki², Takayoshi Kurabayashi¹, Yuji Hosono², Chiho Yamada² and Shinji Sato², ¹Tokai University School of Medicine, Isehara, Kanagawa, Japan, ²Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Dermatomyositis (DM), and particularly the subtype clinically amyopathic DM (CADM), is often associated with fatal rapidly progressive interstitial lung disease (RP-ILD) when anti-melanoma differentiation-associated…
Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 1071 • ACR Convergence 2020
Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore
Choon Guan Chua¹, Jia Zhen Low¹ and Mona Manghani¹, ¹Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: Anti-transcription intermediary factor 1-gamma autoantibody (anti-TIF-1ƴ Ab) associated dermatomyositis (DM) is strongly associated with the occurrence of malignancies. Patients may develop cancers prior to, concurrent…
Abstract Number: 1080 • ACR Convergence 2020
Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America
Antonia Maria Valenzuela Vergara¹, Magdalena Torres¹ and Alejandro Deves¹, ¹Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterized by muscle inflammation and internal organ involvement. The Bohan & Peter (B&P) criteria…
Abstract Number: 1085 • ACR Convergence 2020
Pain in Myositis Is Associated with the Disease Activity
Anjana Chandrasekhara Pillai¹, Chester Oddis², Siamak Moghadam-Kia³, Dana Ascherman⁴, Nicole Neiman⁵, Diane Koontz⁵, Ren Dianxu⁵ and Rohit Aggarwal⁴, ¹UPMC Mckeesport, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵UPMC, Pittsburgh, PA
Background/Purpose: Pain in myositis is poorly studied and multifactorial relating to muscle weakness, arthritis, myofasciitis, fibromyalgia or other co-morbidities. We sought to prospectively evaluate patient-reported…
Abstract Number: 1087 • ACR Convergence 2020
Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis
Yubin Li¹, Christina Bax², Jay Patel³, Adarsh Ravishankar³, Krisha Desai⁴, Majid Zeidi⁴, Muhammad Bashir⁴ and Victoria Werth¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Dermatomyositis (DM) is an acquired inflammatory myopathy characterized by chronic skin inflammation. The pathogenesis of DM is still unclear. Extracellular vesicles (EVs) are lipid…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 1094 • ACR Convergence 2020
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Julie Paik¹, Jemima Albayda¹, Eleni Tiniakou¹, Grazyna Purwin¹, Andrew Koenig² and Lisa Christopher-Stine¹, ¹Johns Hopkins University, Baltimore, MD, ²Pfizer Inc, New York City, NY
Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…
Abstract Number: 0531 • ACR Convergence 2020
The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records
Sunali Goonesekera¹, Ankit Bansal¹, Swarali Tadwalkar² and Alison Isherwood³, ¹Decision Resources Group, Part of Clarivate, Boston, MA, ²Decision Resources Group, part of Clarivate, Bangolore, India, ³Decision Resources Group, part of Clarivate, London, United Kingdom
Background/Purpose: Epidemiological studies suggest differences in the prevalence and disease severity of certain autoimmune diseases by race and ethnicity. In this study, we evaluate the…
Abstract Number: 1098 • ACR Convergence 2020
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez¹, Katherine Pak², Albert Gil-Vila³, Andres Baucells⁴, Benjamin Plotz⁵, Maria Casal-Dominguez⁶, Assia Derfoul⁷, Maria Angeles Martinez⁴, Albert Selva-O'Callaghan³, Sara Sabbagh⁸, Frederick W. Miller¹, Lisa G. Rider⁹, Lisa Christopher-Stine¹⁰ and Andrew Mammen⁶, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Vall d’Hebron Hospital, Barcelona, Spain, ⁴Sant Pau Hospital, Barcelona, Spain, ⁵Division of Rheumatology, New York University Langone Health, New York, NY, ⁶NIH, Bethesda, MD, ⁷NIAMS, NIH, Bethesda, ⁸Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, ⁹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].